ID   UBR2_HUMAN              Reviewed;        1755 AA.
AC   Q8IWV8; O15057; Q4VXK2; Q5TFH6; Q6P2I2; Q6ZUD0;
DT   16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   28-JUN-2023, entry version 181.
DE   RecName: Full=E3 ubiquitin-protein ligase UBR2;
DE            EC=2.3.2.27 {ECO:0000250|UniProtKB:Q6WKZ8};
DE   AltName: Full=N-recognin-2;
DE   AltName: Full=RING-type E3 ubiquitin transferase UBR2;
DE   AltName: Full=Ubiquitin-protein ligase E3-alpha-2;
DE   AltName: Full=Ubiquitin-protein ligase E3-alpha-II;
GN   Name=UBR2; Synonyms=C6orf133, KIAA0349;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND FUNCTION.
RX   PubMed=15548684; DOI=10.1158/0008-5472.can-04-2102;
RA   Kwak K.S., Zhou X., Solomon V., Baracos V.E., Davis J., Bannon A.W.,
RA   Boyle W.J., Lacey D.L., Han H.Q.;
RT   "Regulation of protein catabolism by muscle-specific and cytokine-inducible
RT   ubiquitin ligase E3alpha-II during cancer cachexia.";
RL   Cancer Res. 64:8193-8198(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 481-1755 (ISOFORMS 1/4), AND
RP   VARIANT THR-1095.
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [6]
RP   INTERACTION WITH RECQL4, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15317757; DOI=10.1093/hmg/ddh269;
RA   Yin J., Kwon Y.T., Varshavsky A., Wang W.;
RT   "RECQL4, mutated in the Rothmund-Thomson and RAPADILINO syndromes,
RT   interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway.";
RL   Hum. Mol. Genet. 13:2421-2430(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=16311597; DOI=10.1038/ng1681;
RA   Zenker M., Mayerle J., Lerch M.M., Tagariello A., Zerres K., Durie P.R.,
RA   Beier M., Hulskamp G., Guzman C., Rehder H., Beemer F.A., Hamel B.C.J.,
RA   Vanlieferinghen P., Gershoni-Baruch R., Vieira M.W., Dumic M.,
RA   Auslender R., Gil-da-Silva-Lopes V.L., Steinlicht S., Rauh M., Shalev S.A.,
RA   Thiel C., Winterpacht A., Kwon Y.T., Varshavsky A., Reis A.;
RT   "Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes
RT   pancreatic dysfunction, malformations and mental retardation (Johanson-
RT   Blizzard syndrome).";
RL   Nat. Genet. 37:1345-1350(2005).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   FUNCTION.
RX   PubMed=20298436; DOI=10.1111/j.1365-2443.2010.01385.x;
RA   Kume K., Iizumi Y., Shimada M., Ito Y., Kishi T., Yamaguchi Y., Handa H.;
RT   "Role of N-end rule ubiquitin ligases UBR1 and UBR2 in regulating the
RT   leucine-mTOR signaling pathway.";
RL   Genes Cells 15:339-349(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   INTERACTION WITH CASP8.
RX   PubMed=28602583; DOI=10.1016/j.devcel.2017.05.013;
RA   Weaver B.P., Weaver Y.M., Mitani S., Han M.;
RT   "Coupled Caspase and N-End Rule Ligase Activities Allow Recognition and
RT   Degradation of Pluripotency Factor LIN-28 during Non-Apoptotic
RT   Development.";
RL   Dev. Cell 41:665-673(2017).
RN   [16]
RP   INTERACTION WITH ATXN3.
RX   PubMed=30455355; DOI=10.1074/jbc.ra118.005801;
RA   Weishaeupl D., Schneider J., Peixoto Pinheiro B., Ruess C., Dold S.M.,
RA   von Zweydorf F., Gloeckner C.J., Schmidt J., Riess O., Schmidt T.;
RT   "Physiological and pathophysiological characteristics of ataxin-3
RT   isoforms.";
RL   J. Biol. Chem. 294:644-661(2019).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 98-167 ALONE AND IN COMPLEX WITH
RP   N-END RULE PEPTIDE, UBR-TYPE ZINC FINGER, AND FUNCTION.
RX   PubMed=20835242; DOI=10.1038/nsmb.1894;
RA   Matta-Camacho E., Kozlov G., Li F.F., Gehring K.;
RT   "Structural basis of substrate recognition and specificity in the N-end
RT   rule pathway.";
RL   Nat. Struct. Mol. Biol. 17:1182-1187(2010).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which is a component of the N-end
CC       rule pathway (PubMed:15548684, PubMed:20835242). Recognizes and binds
CC       to proteins bearing specific N-terminal residues that are destabilizing
CC       according to the N-end rule, leading to their ubiquitination and
CC       subsequent degradation (By similarity). Plays a critical role in
CC       chromatin inactivation and chromosome-wide transcriptional silencing
CC       during meiosis via ubiquitination of histone H2A (By similarity). Binds
CC       leucine and is a negative regulator of the leucine-mTOR signaling
CC       pathway, thereby controlling cell growth (PubMed:20298436). Required
CC       for spermatogenesis, promotes, with Tex19.1, SPO11-dependent
CC       recombination foci to accumulate and drive robust homologous chromosome
CC       synapsis (By similarity). Polyubiquitinates LINE-1 retrotransposon
CC       encoded, LIRE1, which induces degradation, inhibiting LINE-1
CC       retrotransposon mobilization (By similarity). Catalyzes ubiquitination
CC       and degradation of the N-terminal part of NLRP1 following NLRP1
CC       activation by pathogens and other damage-associated signals:
CC       ubiquitination promotes degradation of the N-terminal part and
CC       subsequent release of the cleaved C-terminal part of NLRP1, which
CC       polymerizes and forms the NLRP1 inflammasome followed by host cell
CC       pyroptosis (By similarity). {ECO:0000250|UniProtKB:Q6WKZ8,
CC       ECO:0000269|PubMed:15548684, ECO:0000269|PubMed:20298436,
CC       ECO:0000269|PubMed:20835242}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000250|UniProtKB:Q6WKZ8};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000250|UniProtKB:Q6WKZ8}.
CC   -!- SUBUNIT: Interacts with UBE2B; promotes the UBE2B-H2A interaction and
CC       the ubiquitination of histone H2A by UBE2B and UBR2 (By similarity).
CC       Interacts with RECQL4 (PubMed:15317757, PubMed:20835242). Interacts
CC       with TEX19; does not lead to TEX19 degradation and stabilizes it (By
CC       similarity). Interacts with CASP8 (PubMed:28602583). Interacts with
CC       ATXN3 (PubMed:30455355). Interacts with UBE2O (By similarity).
CC       {ECO:0000250|UniProtKB:Q6WKZ8, ECO:0000269|PubMed:15317757,
CC       ECO:0000269|PubMed:20835242, ECO:0000269|PubMed:28602583,
CC       ECO:0000269|PubMed:30455355}.
CC   -!- INTERACTION:
CC       Q8IWV8; P12504: vif; Xeno; NbExp=3; IntAct=EBI-1237260, EBI-779991;
CC       Q8IWV8-2; Q16512: PKN1; NbExp=3; IntAct=EBI-17923957, EBI-602382;
CC       Q8IWV8-2; P51687: SUOX; NbExp=3; IntAct=EBI-17923957, EBI-3921347;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q6WKZ8}.
CC       Chromosome {ECO:0000250|UniProtKB:Q6WKZ8}. Note=Associated with
CC       chromatin during meiosis. {ECO:0000250|UniProtKB:Q6WKZ8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q8IWV8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IWV8-2; Sequence=VSP_015167, VSP_015168;
CC       Name=3;
CC         IsoId=Q8IWV8-3; Sequence=VSP_015166, VSP_015169, VSP_015170,
CC                                  VSP_015171;
CC       Name=4;
CC         IsoId=Q8IWV8-4; Sequence=VSP_017130;
CC   -!- TISSUE SPECIFICITY: Broadly expressed, with highest levels in skeletal
CC       muscle, kidney and pancreas. Present in acinar cells of the pancreas
CC       (at protein level). {ECO:0000269|PubMed:15548684,
CC       ECO:0000269|PubMed:16311597}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal pancreas.
CC       {ECO:0000269|PubMed:16311597}.
CC   -!- DOMAIN: The RING-H2 zinc finger is an atypical RING finger with a His
CC       ligand in place of the fourth Cys of the classical motif.
CC       {ECO:0000269|PubMed:20835242}.
CC   -!- DOMAIN: The UBR-type zinc finger forms a pocket that mediates
CC       recognition of type 1 N-degrons. It exhibits preference for Arginine in
CC       first position, has poor affinity for histidine, and doesn't bind
CC       acetylated peptides. {ECO:0000269|PubMed:20835242}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Derived from mouse cDNA data.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the UBR1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY061884; AAL32101.1; -; mRNA.
DR   EMBL; AK125795; BAC86295.1; -; mRNA.
DR   EMBL; AL049843; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL136223; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL391814; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC024217; AAH24217.1; -; mRNA.
DR   EMBL; BC064512; AAH64512.1; -; mRNA.
DR   EMBL; AB002347; BAA20806.1; -; mRNA.
DR   CCDS; CCDS4870.1; -. [Q8IWV8-1]
DR   CCDS; CCDS55001.1; -. [Q8IWV8-2]
DR   CCDS; CCDS87404.1; -. [Q8IWV8-4]
DR   RefSeq; NP_001171730.1; NM_001184801.1. [Q8IWV8-2]
DR   RefSeq; NP_056070.1; NM_015255.2. [Q8IWV8-1]
DR   RefSeq; XP_005249022.1; XM_005248965.4.
DR   PDB; 3NY2; X-ray; 2.61 A; A/B/C/D/E/F/G/H=98-167.
DR   PDB; 3NY3; X-ray; 1.60 A; A=98-167.
DR   PDB; 5TDA; X-ray; 0.79 A; A=98-168.
DR   PDB; 5TDB; X-ray; 1.10 A; A=98-168.
DR   PDB; 5TDD; X-ray; 1.55 A; A=98-168.
DR   PDB; 5UM3; X-ray; 1.20 A; A=98-167.
DR   PDBsum; 3NY2; -.
DR   PDBsum; 3NY3; -.
DR   PDBsum; 5TDA; -.
DR   PDBsum; 5TDB; -.
DR   PDBsum; 5TDD; -.
DR   PDBsum; 5UM3; -.
DR   AlphaFoldDB; Q8IWV8; -.
DR   BMRB; Q8IWV8; -.
DR   SMR; Q8IWV8; -.
DR   BioGRID; 116896; 153.
DR   DIP; DIP-38165N; -.
DR   IntAct; Q8IWV8; 52.
DR   MINT; Q8IWV8; -.
DR   STRING; 9606.ENSP00000361990; -.
DR   GlyGen; Q8IWV8; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q8IWV8; -.
DR   PhosphoSitePlus; Q8IWV8; -.
DR   BioMuta; UBR2; -.
DR   DMDM; 73622073; -.
DR   EPD; Q8IWV8; -.
DR   jPOST; Q8IWV8; -.
DR   MassIVE; Q8IWV8; -.
DR   MaxQB; Q8IWV8; -.
DR   PaxDb; Q8IWV8; -.
DR   PeptideAtlas; Q8IWV8; -.
DR   ProteomicsDB; 70909; -. [Q8IWV8-1]
DR   ProteomicsDB; 70910; -. [Q8IWV8-2]
DR   ProteomicsDB; 70911; -. [Q8IWV8-3]
DR   ProteomicsDB; 70912; -. [Q8IWV8-4]
DR   Antibodypedia; 30162; 240 antibodies from 32 providers.
DR   DNASU; 23304; -.
DR   Ensembl; ENST00000372899.6; ENSP00000361990.1; ENSG00000024048.11. [Q8IWV8-1]
DR   Ensembl; ENST00000372901.2; ENSP00000361992.1; ENSG00000024048.11. [Q8IWV8-4]
DR   Ensembl; ENST00000372903.6; ENSP00000361994.2; ENSG00000024048.11. [Q8IWV8-2]
DR   GeneID; 23304; -.
DR   KEGG; hsa:23304; -.
DR   MANE-Select; ENST00000372901.2; ENSP00000361992.1; NM_001363705.2; NP_001350634.1. [Q8IWV8-4]
DR   UCSC; uc003osf.4; human. [Q8IWV8-1]
DR   AGR; HGNC:21289; -.
DR   CTD; 23304; -.
DR   DisGeNET; 23304; -.
DR   GeneCards; UBR2; -.
DR   HGNC; HGNC:21289; UBR2.
DR   HPA; ENSG00000024048; Low tissue specificity.
DR   MIM; 609134; gene.
DR   neXtProt; NX_Q8IWV8; -.
DR   OpenTargets; ENSG00000024048; -.
DR   PharmGKB; PA128394621; -.
DR   VEuPathDB; HostDB:ENSG00000024048; -.
DR   eggNOG; KOG1140; Eukaryota.
DR   GeneTree; ENSGT00950000183075; -.
DR   HOGENOM; CLU_055226_0_0_1; -.
DR   InParanoid; Q8IWV8; -.
DR   OMA; GEASYMC; -.
DR   OrthoDB; 51389at2759; -.
DR   PhylomeDB; Q8IWV8; -.
DR   TreeFam; TF323875; -.
DR   PathwayCommons; Q8IWV8; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q8IWV8; -.
DR   SIGNOR; Q8IWV8; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 23304; 9 hits in 1200 CRISPR screens.
DR   ChiTaRS; UBR2; human.
DR   EvolutionaryTrace; Q8IWV8; -.
DR   GeneWiki; UBR2; -.
DR   GenomeRNAi; 23304; -.
DR   Pharos; Q8IWV8; Tbio.
DR   PRO; PR:Q8IWV8; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q8IWV8; protein.
DR   Bgee; ENSG00000024048; Expressed in secondary oocyte and 209 other tissues.
DR   Genevisible; Q8IWV8; HS.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IBA:GO_Central.
DR   GO; GO:0140852; F:histone ubiquitin ligase activity; ISS:UniProtKB.
DR   GO; GO:0070728; F:leucine binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0071233; P:cellular response to leucine; IDA:UniProtKB.
DR   GO; GO:0031507; P:heterochromatin formation; ISS:UniProtKB.
DR   GO; GO:0033522; P:histone H2A ubiquitination; IBA:GO_Central.
DR   GO; GO:0007141; P:male meiosis I; IEA:Ensembl.
DR   GO; GO:0007140; P:male meiotic nuclear division; ISS:UniProtKB.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; IMP:UniProtKB.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; ISS:UniProtKB.
DR   GO; GO:0010526; P:retrotransposon silencing; ISS:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   GO; GO:0071596; P:ubiquitin-dependent protein catabolic process via the N-end rule pathway; IBA:GO_Central.
DR   CDD; cd16686; RING-H2_UBR2; 1.
DR   CDD; cd19679; UBR-box_UBR2; 1.
DR   Gene3D; 2.10.110.30; -; 1.
DR   Gene3D; 3.30.1390.10; -; 1.
DR   Gene3D; 1.10.10.2670; E3 ubiquitin-protein ligase; 1.
DR   InterPro; IPR003769; ClpS_core.
DR   InterPro; IPR042065; E3_ELL-like.
DR   InterPro; IPR044046; E3_ligase_UBR-like_C.
DR   InterPro; IPR014719; Ribosomal_L7/12_C/ClpS-like.
DR   InterPro; IPR047508; UBR-box_UBR2.
DR   InterPro; IPR039164; UBR1-like.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   InterPro; IPR003126; Znf_UBR.
DR   PANTHER; PTHR21497:SF28; E3 UBIQUITIN-PROTEIN LIGASE UBR2; 1.
DR   PANTHER; PTHR21497; UBIQUITIN LIGASE E3 ALPHA-RELATED; 1.
DR   Pfam; PF02617; ClpS; 1.
DR   Pfam; PF18995; PRT6_C; 1.
DR   Pfam; PF02207; zf-UBR; 1.
DR   SMART; SM00396; ZnF_UBR1; 1.
DR   SUPFAM; SSF54736; ClpS-like; 1.
DR   SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1.
DR   PROSITE; PS51157; ZF_UBR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromosome; Coiled coil;
KW   Metal-binding; Nucleus; Reference proteome; Transferase;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..1755
FT                   /note="E3 ubiquitin-protein ligase UBR2"
FT                   /id="PRO_0000056140"
FT   ZN_FING         97..168
FT                   /note="UBR-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00508"
FT   ZN_FING         1108..1214
FT                   /note="RING-type; atypical"
FT   REGION          1004..1034
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1261..1287
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          1019..1054
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        1018..1034
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1261..1279
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   VAR_SEQ         1..496
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_015166"
FT   VAR_SEQ         397..439
FT                   /note="QQLQRDFMEDDHERAVSVTALSVQFFTAPTLARMLITEENLMS -> ERLQS
FT                   DYVTDDHDREFSVADLSVQIFTVPSLFSISAGRSGSPL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015167"
FT   VAR_SEQ         397..426
FT                   /note="QQLQRDFMEDDHERAVSVTALSVQFFTAPT -> ERLQSDYVTDDHDREFSV
FT                   ADLSVQIFTVPS (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_017130"
FT   VAR_SEQ         440..1755
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015168"
FT   VAR_SEQ         497..514
FT                   /note="RQKFLEGFDAFLELLKCM -> MYAGNIPIYKTESRSRNE (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_015169"
FT   VAR_SEQ         1022..1071
FT                   /note="SSRDKDKAERKRKAEIARLRREKIMAQMSEMQRHFIDENKELFQQTLELD
FT                   -> HNFRVQGTKTKLRGREKQRLPDCAEKRSWLRCLKCSGILLMKTKNSFSRH (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_015170"
FT   VAR_SEQ         1072..1755
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_015171"
FT   VARIANT         172
FT                   /note="E -> D (in dbSNP:rs6905054)"
FT                   /id="VAR_052117"
FT   VARIANT         1095
FT                   /note="A -> P (in dbSNP:rs6917033)"
FT                   /id="VAR_059816"
FT   VARIANT         1095
FT                   /note="A -> S (in dbSNP:rs6917033)"
FT                   /id="VAR_059817"
FT   VARIANT         1095
FT                   /note="A -> T (in dbSNP:rs6917033)"
FT                   /evidence="ECO:0000269|PubMed:9205841"
FT                   /id="VAR_023283"
FT   CONFLICT        864
FT                   /note="K -> R (in Ref. 2; BAC86295)"
FT                   /evidence="ECO:0000305"
FT   STRAND          108..112
FT                   /evidence="ECO:0007829|PDB:5TDA"
FT   TURN            113..115
FT                   /evidence="ECO:0007829|PDB:5TDA"
FT   STRAND          116..118
FT                   /evidence="ECO:0007829|PDB:5TDA"
FT   HELIX           125..129
FT                   /evidence="ECO:0007829|PDB:5TDA"
FT   HELIX           132..135
FT                   /evidence="ECO:0007829|PDB:5TDA"
FT   STRAND          138..142
FT                   /evidence="ECO:0007829|PDB:5TDA"
FT   TURN            154..156
FT                   /evidence="ECO:0007829|PDB:5TDA"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:5TDA"
FT   TURN            164..166
FT                   /evidence="ECO:0007829|PDB:5TDA"
SQ   SEQUENCE   1755 AA;  200538 MW;  04B14FCB13E21808 CRC64;
     MASELEPEVQ AIDRSLLECS AEEIAGKWLQ ATDLTREVYQ HLAHYVPKIY CRGPNPFPQK
     EDMLAQHVLL GPMEWYLCGE DPAFGFPKLE QANKPSHLCG RVFKVGEPTY SCRDCAVDPT
     CVLCMECFLG SIHRDHRYRM TTSGGGGFCD CGDTEAWKEG PYCQKHELNT SEIEEEEDPL
     VHLSEDVIAR TYNIFAITFR YAVEILTWEK ESELPADLEM VEKSDTYYCM LFNDEVHTYE
     QVIYTLQKAV NCTQKEAIGF ATTVDRDGRR SVRYGDFQYC EQAKSVIVRN TSRQTKPLKV
     QVMHSSIVAH QNFGLKLLSW LGSIIGYSDG LRRILCQVGL QEGPDGENSS LVDRLMLSDS
     KLWKGARSVY HQLFMSSLLM DLKYKKLFAV RFAKNYQQLQ RDFMEDDHER AVSVTALSVQ
     FFTAPTLARM LITEENLMSI IIKTFMDHLR HRDAQGRFQF ERYTALQAFK FRRVQSLILD
     LKYVLISKPT EWSDELRQKF LEGFDAFLEL LKCMQGMDPI TRQVGQHIEM EPEWEAAFTL
     QMKLTHVISM MQDWCASDEK VLIEAYKKCL AVLMQCHGGY TDGEQPITLS ICGHSVETIR
     YCVSQEKVSI HLPVSRLLAG LHVLLSKSEV AYKFPELLPL SELSPPMLIE HPLRCLVLCA
     QVHAGMWRRN GFSLVNQIYY YHNVKCRREM FDKDVVMLQT GVSMMDPNHF LMIMLSRFEL
     YQIFSTPDYG KRFSSEITHK DVVQQNNTLI EEMLYLIIML VGERFSPGVG QVNATDEIKR
     EIIHQLSIKP MAHSELVKSL PEDENKETGM ESVIEAVAHF KKPGLTGRGM YELKPECAKE
     FNLYFYHFSR AEQSKAEEAQ RKLKRQNRED TALPPPVLPP FCPLFASLVN ILQSDVMLCI
     MGTILQWAVE HNGYAWSESM LQRVLHLIGM ALQEEKQHLE NVTEEHVVTF TFTQKISKPG
     EAPKNSPSIL AMLETLQNAP YLEVHKDMIR WILKTFNAVK KMRESSPTSP VAETEGTIME
     ESSRDKDKAE RKRKAEIARL RREKIMAQMS EMQRHFIDEN KELFQQTLEL DASTSAVLDH
     SPVASDMTLT ALGPAQTQVP EQRQFVTCIL CQEEQEVKVE SRAMVLAAFV QRSTVLSKNR
     SKFIQDPEKY DPLFMHPDLS CGTHTSSCGH IMHAHCWQRY FDSVQAKEQR RQQRLRLHTS
     YDVENGEFLC PLCECLSNTV IPLLLPPRNI FNNRLNFSDQ PNLTQWIRTI SQQIKALQFL
     RKEESTPNNA STKNSENVDE LQLPEGFRPD FRPKIPYSES IKEMLTTFGT ATYKVGLKVH
     PNEEDPRVPI MCWGSCAYTI QSIERILSDE DKPLFGPLPC RLDDCLRSLT RFAAAHWTVA
     SVSVVQGHFC KLFASLVPND SHEELPCILD IDMFHLLVGL VLAFPALQCQ DFSGISLGTG
     DLHIFHLVTM AHIIQILLTS CTEENGMDQE NPPCEEESAV LALYKTLHQY TGSALKEIPS
     GWHLWRSVRA GIMPFLKCSA LFFHYLNGVP SPPDIQVPGT SHFEHLCSYL SLPNNLICLF
     QENSEIMNSL IESWCRNSEV KRYLEGERDA IRYPRESNKL INLPEDYSSL INQASNFSCP
     KSGGDKSRAP TLCLVCGSLL CSQSYCCQTE LEGEDVGACT AHTYSCGSGV GIFLRVRECQ
     VLFLAGKTKG CFYSPPYLDD YGETDQGLRR GNPLHLCKER FKKIQKLWHQ HSVTEEIGHA
     QEANQTLVGI DWQHL
//
